A number of stocks jumped in the afternoon session after comments from a key Federal Reserve official bolstered hopes for an ...

In honor of National Diabetes Awareness Month, DAV (Disabled American Veterans) announced today a new strategic partnership with Dexcom, the global leader in glucose biosensing. As part of the ...

Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of DexCom, Inc. between July 26, 2024 and September 17, 2025, both dates inclusive (the "Class Period") of the ...

DXCM's strong Q3 growth, expanding CGM coverage and innovation-driven momentum position it for sustained adoption despite rising competition.

Levi & Korsinsky, LLP notifies investors in DexCom, Inc. (NASDAQ: DXCM) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of DexCom, Inc. investors ...

Looking back on patient monitoring stocks’ Q3 earnings, we examine this quarter’s best and worst performers, including DexCom (NASDAQ:DXCM) and its peers.

Rising costs and complex care make diabetes a daily challenge. Local patient and pharmacy expert share strategies, struggles, ...

Q3 2025 Earnings Call Transcript October 30, 2025 DexCom, Inc. beats earnings expectations. Reported EPS is $0.61, expectations were $0.57. Operator: Ladies and gentlemen, welcome to the DexCom Third ...

Dexcom's solid third-quarter report was overshadowed Friday by its "surprisingly cautious" outlook, and Dexcom stock tumbled.

A defense tech darling's stock surged on Monday, Nov. 10, 2025, amid hopes that the government may reopen soon, while comments from President Trump calling for changes to health care payments dragged ...

Soft earnings and steep spending plans weighed on a food delivery firm on Thursday, Nov. 6, 2025, while a cloud security platform got a boost from AI-driven growth.

As Pfizer acquires MET-097 maker Metsera, phase 2 data show potential for greater tolerability and once-monthly dosing.